ClinicalTrials.gg
CompletedNCT04952948Updated Jul 7, 2021

Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes

An interventional study of PILATES Training in Type-2 Diabetes, Physical Disability and Blood Pressure, sponsored by Universidade Federal do vale do São Francisco. Completed. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by Universidade Federal do vale do São Francisco · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Aug 2016, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Study summary

Type 2 diabetes mellitus (T2D) is a chronic inflammatory disease that is associated with loss of functional capacity and increased blood pressure. Coupled with this, there is an increased risk of falls and fractures in patients with T2D. On the other hand, conventional training programs for resistance, aerobic or combined exercises are strongly recommended for people with T2D, as they promote a reduction in the glycemic rate and blood pressure, and an improvement in functional capacity. However, little is known about unconventional training programs such as PILATES (dynamic and isometric muscle actions) on functional capacity and cardiovascular adaptations in T2D.

Read the detailed description

Type 2 diabetes mellitus (T2D) is a chronic inflammatory disease whose main mechanism of installation is insulin resistance and is associated with loss of functional capacity with consequent fragility and increased blood pressure. Currently, women have the highest prevalence of T2D in Brazil. Previous studies have shown that women are more affected by cases of hospitalization and that they have a higher risk of mortality due to illness. Muscle function and strength in patients with T2D show a reduction compared to healthy and normoglycemic subjects, especially in menopausal women, when estrogen declines with a consequent increase in body fat and decreased muscle quality. Coupled with this, there is a reduction in muscle mass and an increased risk of falls and fractures in patients with T2D. Its association with other factors such as physical inactivity, involuntary weight loss, less muscle strength and slower gait can lead to frailty and limit the performance of basic daily activities. On the other hand, conventional training programs for resistance, aerobic or combined exercises are strongly recommended for people with T2D, as they promote a reduction in the glycemic rate and blood pressure, and an improvement in functional capacity. Unconventional training programs such as PILATES (dynamic and isometric muscle actions) ensure the control of forces that act on the musculoskeletal system, promoting an important improvement in functional capacity and possible cardiovascular adaptations. Additionally, elderly people have pronounced losses of neuromuscular adaptations even in a short period of detraining, compromising gains related to functional capacity and this loss can be even more pronounced in patients with T2D. Therefore, it is also necessary for training professionals to understand the effects of the short detraining period after unconventional exercise programs like PILATES on the functional capacity of elderly women with T2D as well as to understand the effects of the PILATES training on blood pressure or cardiovascular adaptations.

02

Conditions studied

  • Type-2 Diabetes
  • Physical Disability
  • Blood Pressure

Browse trials for

Keywords

  • Resistance exercise
  • Functionality
  • Interruption
  • Diabetes
  • Cardiovascular
03

In context

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

This study's enrollment of 22 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Universidade Federal do vale do São Francisco is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present a diagnosis of type-2 diabetes;
  • Do not have severe or decompensated heart disease;
  • Do not have coronary artery disease;
  • Do not have peripheral neuropathy and ulcers in the extremities;
  • Do not have severe skin lesions;
  • Do not have proliferative retinopathy;
  • Do not have insulin therapy;
  • Do not have any health condition that would hinder participation in the exercise sessions.

Exclusion criteria

Exclusion Criteria:

  • Present some unexpected abnormality in health conditions during the research;
  • Do not participate in more than 80% of the training sessions in the PILATES group.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    PILATES Method Training Group

    The PILATES program at moderate intensity lasted 12 weeks, at a frequency of 3 times a week, and with duration of 60 minutes for each exercise session.

    Other: PILATES Training

  • Sham comparator
    CONTROL Group

    While the PILATES Group participated in the intervention with physical exercises, the CONTROL group only participated in the functional capacity and blood pressure assessments. However, at the end of the intervention in the PILATES Group, the CONTROL Group was invited to participate in a similar training program.

    Other: PILATES Training

Interventions

  • OtherPILATES Training

    During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.

06

What researchers measure

Primary outcomes

  1. Change in functional capacity in type-2 diabetes

    Measurements of functional capacity (time in seconds of execution of the functional tests) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 4 weeks of intervention in PILATES Group and CONTROL group

  2. Change in functional capacity in type-2 diabetes

    Measurements of functional capacity (time in seconds of execution of the functional tests) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 8 weeks of intervention in PILATES Group and CONTROL group

  3. Change in functional capacity in type-2 diabetes

    Measurements of functional capacity (time in seconds of execution of the functional tests) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 12 weeks post-intervention in PILATES Group and CONTROL group

  4. Change in functional capacity in type-2 diabetes

    Measurements of functional capacity (time in seconds of execution of the functional tests) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and detraining moments.

    Time frame: Pre-intervention (week zero) versus 4 weeks of detraining post-intervention in PILATES Group and CONTROL group

  5. Change in functional capacity in type-2 diabetes

    Measurements of functional capacity (time in seconds of execution of the functional tests) in the PILATES and CONTROL groups to be analyzed in the post-intervention and detraining moments.

    Time frame: Pos-intervention (12 weeks) versus 4 weeks of detraining (4W_DT) in PILATES Group and CONTROL group

  6. Change in blood pressure in type-2 diabetes

    Measurements of systolic blood pressure and diastolic blood pressure (mmHg) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 4 weeks of intervention in PILATES Group and CONTROL group

  7. Change in lood pressure in type-2 diabetes

    Measurements of systolic blood pressure and diastolic blood pressure (mmHg) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 8 weeks of intervention in PILATES Group and CONTROL group

  8. Change in blood pressure in type-2 diabetes

    Measurements of systolic blood pressure and diastolic blood pressure (mmHg) in the PILATES and CONTROL groups to be analyzed in the pre-intervention and post-intervention moments.

    Time frame: Pre-intervention (week zero) versus 12 weeks post-intervention in PILATES Group and CONTROL group

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Melo KCB, Araujo FS, Cordeiro Junior CCM, de Andrade KTP, Moreira SR. Pilates Method Training: Functional and Blood Glucose Responses of Older Women With Type 2 Diabetes. J Strength Cond Res. 2020 Apr;34(4):1001-1007. doi: 10.1519/JSC.0000000000002704. PubMed 29985228 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Nov 2016, 3 months.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 3 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jul 7, 2021
StartActual
Aug 23, 2016
Primary completionActual
Nov 28, 2016
CompletionActual
Dec 19, 2016
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04952948
Lead sponsor
Universidade Federal do vale do São Francisco
Responsible party
Sérgio Rodrigues Moreira (Professor (PhD), Universidade Federal do vale do São Francisco) — Principal investigator
First posted
Jul 7, 2021
Start date
Aug 23, 2016
Primary completion
Nov 28, 2016
Completion
Dec 19, 2016
Last update
Jul 7, 2021

Study contacts

Ilka Yolane TP Andrade, Ms
study chair · Federal University of Vale do São Francisco - UNIVASF

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion